This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

Mechanism of Action  Dosing Dosing Dosing Information Dose Adjustments Drug Interactions Efficacy & Trial Design Efficacy Efficacy Trial Design Safety & Tolerability Support & ResourcesSupport &
​​​​​​​Resources
Materials Videos Frequently Asked Questions
Dose Adjustments1​​​​​​​Dosing adjustments for renal impairment1
  • For moderate renal impairment (eGFR ≥30 to <60 mL/min), the dose of PAXLOVID should be reduced to 1 nirmatrelvir tablet and 1 ritonavir tablet, twice daily for 5 days.
For 5 consecutive days1 Morning Dose
  • One pink 150-mg tablet of nirmatrelvir
  • One white 100-mg tablet of ritonavir

Patients should take both tablets together.

Evening Dose
  • One pink 150-mg tablet of 
    nirmatrelvir
  • One white 100-mg tablet of ritonavir

Patients should take both tablets together.

  • No dose adjustment of PAXLOVID is required for patients with mild renal impairment (eGFR ≥60 to <90 mL/min)​​​​​​​
  • PAXLOVID is not recommended in patients with severe renal impairment (eGFR <30 mL/min)
Dosing adjustments for mild or moderate hepatic impairment1
  • No dose adjustment of PAXLOVID is required for patients with either mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment
  • PAXLOVID is not recommended in patients with severe hepatic impairment​​​​​​​
EXPLORE MOREEfficacy & trial design

Discover the efficacy data and trial design of EPIC-HR. 

Efficacy Loading Trial design Loading
Reference:
  1. PAXLOVID Summary of Product Characteristics. https://www.medicines.ie/medicines/paxlovid-150-mg-100-mg-film-coated-tablets-35210/spc (Accessed October 2023).
Dosing Drug Interaction Finder

Easily search for drug interactions by active substance name or keywords.

Search Loading
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Legal Category: S1A
Further information is available upon request

PP-PAX-IRL-0172. October 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024